There are no data on the safety and efficacy of the new coronavirus vaccine in AIDS patients, and this needs to be determined by the type of vaccination and the patient’s condition.
The immune response and protective effect of the vaccine may be reduced in the AIDS population. For inactivated and recombinant subunit vaccines, according to the safety characteristics of previous vaccines of the same type, vaccination is recommended if the patient’s condition is currently stable; if the patient is in the acute infectious stage, vaccination is postponed.
For adenovirus vector vaccine, although the vector virus used is replication-defective, there is no previous safety data on the use of the same type of vaccine, and it is recommended to be vaccinated after adequate notification that the benefits outweigh the risks for the individual.
At the same time, the general public is advised not to go to crowded places, avoid medium and high-risk areas, wear masks when going out, and keep a certain distance from others. If you come into contact with an infected person inadvertently, you must report it positively and cooperate with the relevant authorities to quarantine the person in order to avoid infecting more people.